PPBT News & Events

Purple Biotech trading halted, news pending

Purple Biotech announced that it intends to change the ratio of american depositary shares to its ordinary shares from the current ADS ratio of one ADS representing 200 ordinary shares, to a new ADS ratio of one ADS representing 2,000 ordinary shares. For the company's ADS holders, the ADS ratio change will have the same effect as a one-for-ten reverse ADS split. The ADS ratio change is expected to become effective at the beginning of trading on or about March 2. The primary purpose of the ADS ratio change is to enable the company to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Purple Biotech announced successful completion of a non-human primates toxicology study of IM1240, a tri-specific antibody from its CAPTN-3 platform that targets 5T4, a tumor-specific antigen expressed on multiple solid tumors. "The Study demonstrated that IM1240's proprietary capping technology enabled dosing at levels up to 300-fold higher than a non-capped comparator, with significantly reduced immune-related toxicity, including minimal cytokine release. These results highlight the unique safety profile of this approach, which may address a key limitation of certain current T cell engagers, where cytokine release syndrome can restrict dosing," the company said.

Purple Biotech reported positive new preclinical data from its CAPTN-3 tri-specific antibody platform presented at the ESMO Immuno-Oncology Congress 2025. These new preclinical data demonstrates that two CAPTN-3 tri-specific antibodies, IM1240 and IM1305, each achieve strong anti-tumor activity across different tumor antigens. IM1240 has also shown anti-tumor activity in models resistant to prior PD1 therapy. These results support the platform's potential applicability across a range of solid tumors. The company's lead CAPTN-3 program, IM1240, demonstrated significant anti-tumor activity in three PD1-resistant ex-vivo models, including new results in HNSCC patient-derived biopsies. In these studies, IM1240 induced tumor cell apoptosis, with anti-tumor activity dependent on both CD3 and NKG2A arms. The company's new TROP2-targeting candidate, IM1305, further validates the adaptability of the CAPTN-3 platform and demonstrated high-affinity binding to both TROP2 and NKG2A. Potent PBMC-mediated tumor cell killing was observed at low concentrations across multiple tumor types, including triple-negative breast, gastric, pancreatic, and head and neck cancers. In humanized triple-negative breast cancer mouse models, IM1305 induced sustained tumor regression at low doses.